This trial is evaluating whether Intravenous digoxin will improve 1 primary outcome, 5 secondary outcomes, and 10 other outcomes in patients with Hepatitis, Toxic. Measurement will happen over the course of Up to 28 days.
This trial requires 60 total participants across 2 different treatment groups
This trial involves 2 different treatments. Intravenous Digoxin is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"About 8.2% of American adults ages 19 and up are infected with viral hepatitis or chronic liver diseases every year. The prevalence of hepatitis A is 1.3% while 0.8% are infected with hepatitis B. The prevalence of hepatitis C infecting people 20 years or older has been estimated around 2.3%, while 0.7% are estimated to be infected with hepatitis D. Hepatitis E is estimated around 1 per 2,500 people. In 2000 about 1.8% of American adults were infected with chronic liver disease." - Anonymous Online Contributor
"Hepatitis, a common liver condition in humans, is a viral disease in which it damage to the liver. Because hepatitis is a general disease, the exact cause of all types of it not yet known, while some viruses are known to cause disease, there are still many types of hepatitis for which it not yet known what causes it, so many types of hepatitis. There is a wide variety of hepatitis from the most common to the rarest. Hepatitis B (HBV) and Hepatitis C (HCV) are the most dangerous, known causes of liver disease due to hepatitis in humans." - Anonymous Online Contributor
"Most treatments for chronic liver diseases are symptomatic. The diagnosis and/or treatment of HBV and HCV, are usually prescribed by a physician, in most countries." - Anonymous Online Contributor
"Hepatitis C can be cured, provided medical treatment is successful. In the absence of cirrhosis, HBeAg seroconversion occurs in 60% of HBeAg-negative cases in 9 to 12 months. Cirrhosis requires a higher seroconversion rate of over 60%. The likelihood of cure drops dramatically with increased grades of fibrosis." - Anonymous Online Contributor
"A diverse range of environmental exposures, medical and psychiatric, may trigger hepatitis. Hepatocellular carcinoma may occur in many types of liver disease. Prevention of hepatitis is based on vaccination and safe drinking water use, and, for individuals at risk, timely diagnosis and appropriate treatment." - Anonymous Online Contributor
"Signs of hepatitis will not be experienced by any person, because patients typically lack the clinical symptoms. The signs of hepatitis are those that are associated with liver damage, and include itchiness, jaundice, and fever. The main features of patients with severe hepatitis include rapid deterioration of liver function and liver transplantation or liver failure. The severity of symptoms can be influenced by the immune status of the individual. In the UK, most patients with hepatitis die within the first week of their infection. Therefore, when testing a person for hepatitis, it is not useful to rely on clinical suspicion alone. It is also important to do some sort of lab test." - Anonymous Online Contributor
"For patients with chronic heart failure and significant chronic liver disease, intravenous digoxin appears to reduce morbidity and mortality. This benefit is not obtained by treating patients with oral digoxin after they become digoxigenously st uped." - Anonymous Online Contributor
"Most adult cases of hepatitis B (72%) and hepatitis A (67%) occurred between the ages of 18 and 24 years (range, 16-55 years). Most cases of hepatitis B tended to occur younger than age 30 years (range, 20-34 years), because of [early childbearing and promiscuous behaviors of males of certain age range] as well as the greater prevalence of HB infection in young adults in Guangxi Province. However, all children with HBV infection need to get tested periodically regardless of their ages, because even young infants are in danger of infection. The prevalence of HBV infection in children younger than 15 years is increasing." - Anonymous Online Contributor
"Use of iv digoxin is safe and effective for the treatment of heart failure owing to heart failure or atrial fibrillation, and was better than any placebo (P<0.0001). Digoxin may be used as a therapy in patients receiving an implantable cardioverter-defibrillator." - Anonymous Online Contributor
"There are multiple hepatitis research activities at OUPHMS, including clinical trials and meta-analyses, and you can check out the latest news from OUPHMS’ web site. The website provides information detailing where to find recent articles in Hepatitis and links to relevant clinical trials. For example, there is an overview of the latest research on hepatitis C." - Anonymous Online Contributor
"Clinical trials are not reported on in this journal. However, it seems likely that this would meet the Journal's usual inclusion criteria given the wide range of intravenous digoxin formulations used in clinical practice to treat heart diseases as well as its use under routine clinical conditions." - Anonymous Online Contributor
"The recommended dose of one i.v. dose of digoxin 0.125 mg/kg does not result in either serious or nonfatal adverse event in children who have normal left ventricular function, but with moderate to severe pulmonary disease. No deaths have occurred in these children who received digoxin. Because of the safety profile, digoxin can be given by i.v. route in patients with moderate to severe pulmonary disease but with a normal left ventricular function." - Anonymous Online Contributor